InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): Update and future directions

Blood

Volumn 116, Issue 20, 2010, Pages

  Turner, Jennifer J ^a   Morton, Lindsay M ^b   Linet, Martha S ^b   Clarke, Christina A ^c   Kadin, Marshall E ^d   Vajdic, Claire M ^e   Monnereau, Alain ^f,g   Maynadiè, Marc ^h   Chiu, Brian C H ⁱ   Marcos Gragera, Rafael ^j   Costantini, Adele Seniori ^k   Cerhan, James R ^l   Weisenburger, Dennis D ^m  

^a MACQUARIE UNIVERSITY   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f INSTITUT BERGONIÉ   (France)

^g CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^h UNIVERSITÉ DE BOURGOGNE   (France)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^k CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RESEARCH; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION; LARGE CELL LYMPHOMA; LYMPHOID TISSUE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PUBLICATION; WORLD HEALTH ORGANIZATION;

EID: 78549248915     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-289561     Document Type: Article

References (43)

1. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110(2):695-708.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics, Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
3. Percy C, Fritz A, Ries L. Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, second edition, to International Classification of Diseases for Oncology, 3d ed. Cancer Statistics Branch, DCCPS, SEER Program, National Cancer Institute; 2001.
4. Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008;112(13):5150-5160.
5. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109(8):3479-3488. (Pubitemid 46572538)
6. Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non-Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer. 2008;122(1):144-154.
7. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer. 2008;122(9):2062-2070.
8. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038.
9. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451-458. (Pubitemid 351447318)
10. Vajdic CM, Falster MO, de Sanjose S, et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res. 2009;69(16):6482-6489.
11. Sant M, Allemani C, De Angelis R, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer. 2008;44(4):579-587.
12. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2006/, based on November 2008 SEER data submission, posted to the SEER website, 2009. Accessed April 30, 2010.
13. Swerdlow S, Campo E, Harris N. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
14. Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S27-S32.
15. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241(6):471-475.
16. Swerdlow SH, Berger F, Pileri SA, Harris NL, Jaffe ES, Stein H. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008:194-195.
17. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol. 2005;162(12):1153-1161.
18. Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter pylori-associated global gastric cancer burden. Front Biosci. 2009;14:1490-1504.
19. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931-3937.
20. Kadin ME. Pathobiology of CD30+ cutaneous T-cell lymphomas. J Cutan Pathol. 2006;33(1 suppl):10-17.
21. Xu JX, Hoshida Y, Yang WI, et al. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: a case-control study in East Asia. Int J Cancer. 2007;120(2):406-410.
22. Morales-Suarez-Varela MM, Olsen J, Johansen P, et al. Occupational risk factors for mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2004;46(3):205-211. (Pubitemid 38366624)
23. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-3394.
24. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386-6391.
25. Baecklund E, Backlin C, Iliadou A, et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum. 2006;54(12):3774-3781. (Pubitemid 44955877)
26. Vajdic CM, Van Leeuwen MT, Turner JJ, et al. No excess risk of follicular lymphoma in kidney transplant and HIV-related immune deficiency. Int J Cancer. 2010;127(11):2732-2735.
27. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
28. Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433-5439.
29. Johnson CH, Adamo M, Peace S, Percy-Laurry A. Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual National Cancer Institute, Bethesda, MD, 20892-8316. http://seer.cancer. gov/tools/heme/index.html; 2010. Accessed April 30, 2010.
30. Kim H, Hendrickson R, Dorfman RF. Composite lymphoma. Cancer. 1977;40(3):959-976.
31. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
32. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
33. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
34. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
35. Roberts RA, Sabalos CM, LeBlanc ML, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest. 2007;87(10):979-997.
36. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112(8):3425-3433.
37. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183-3190. (Pubitemid 41565917)
38. Chiu BC, Lan Q, Dave BJ, Blair A, Zahm SH, Weisenburger DD. The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma. J Natl Cancer Inst Monogr. 2008;(39):69-73.
39. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114(4):826-834.
40. Edge SE, Byrd DR, Carducci MA, Compton CA, eds. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.
41. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
42. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
43. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.